WO2018200223A1 - Oral microbiota promoting composition and method - Google Patents
Oral microbiota promoting composition and method Download PDFInfo
- Publication number
- WO2018200223A1 WO2018200223A1 PCT/US2018/027604 US2018027604W WO2018200223A1 WO 2018200223 A1 WO2018200223 A1 WO 2018200223A1 US 2018027604 W US2018027604 W US 2018027604W WO 2018200223 A1 WO2018200223 A1 WO 2018200223A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- oral cavity
- oral
- sugar
- microbiota
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/719—Pullulans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the disclosure generally relates to oral cavity microbiota promoting compositions including sweetened prebiotic foods and methods for making and using the same. More
- compositions and methods for making and using the same that may have the advantageous effect of modulating the oral microbiota which may thereby promote the naturally occurring health of the immune system including reducing respiratory allergic reactions.
- oral hygiene hypothesis is one aspect of a more general hygiene hypothesis (HH) , which was proposed more than two decades ago ( see Strachan, D.P. "Hay fever, hygiene, and household size", British Medical Journal 299, 1259-1260 (1989)) to explain the rise in allergic diseases.
- Numerous scientific studies have since provided support for HH, generally showing a relation between increased exhibition of allergies in association with modern social practices, such as formula infant feeding, antibiotic use, urban living, and reduction in family size (see e.g., Okada, H. , Kuhn, C. ,
- compositions including an oral cavity microbiota promoting substance and method of using the same that has the effect of promoting a healthy oral microbiota that promotes the healthy operation of the immune system which may have the functional effect of promoting an improved response to allergens .
- a method of promoting a desired oral microbiota in a subject to treat an allergy related respiratory condition including providing an edible composition including an amino acid containing ingredient comprising L-arginine wherein the composition is provided contained and at least partially dissolved within an oral cavity of the subject for a period of at least from about 10 seconds to about 1 hour on a daily basis of at least two consecutive days.
- microbiota-promoting substances may promote desired naturally occurring oral bacteria species/strains, which may in turn have an associated effect of modulating or reducing the intensity of certain types of allergic reactions, including those associated with allergic rhinitis (AR) one of the most common allergic reactions including symptoms such as any combination of a runny or stuffy nose, sneezing, itchy/red eyes, coughing, and congestion.
- AR allergic rhinitis
- oral microbiota interact with the host largely through metabolites produced by its relevant bacterial members.
- Those metabolites may influence the function of multiple biologic systems and organs, such as the immune system. Missing or severe reduction of the relevant bacteria may cause malfunctioning of the immune system, such as causing over sensitivity to allergens .
- the immune system response to the allergen may be modulated such that the associated allergic reaction symptoms are suppressed relative to what an allergic reaction may be with an unhealthy level of or different microbiota. It is further believed and evidence suggests that over time, as a result of promoting a healthy oral microbiota with selected microbiota-promoting substances that the immune system may function in a healthy manner with a healthy response to allergens.
- a healthy oral microbiota may lead to a healthy microbiota in the lungs as well.
- the method may benefit the healthy functioning of the immune system which may in turn have a healthy response not only to allergic rhinitis but also the relevant diseases in the lungs, such as asthma.
- an oral microbiota promoting composition may be provided into an oral cavity that may have the effect of promoting desired microbiota within an oral cavity.
- a method of applying an oral microbiota promoting composition may be provided that may have the effect of promoting desired microbiota within an oral cavity and have the desired functional effect of treating a respiratory condition including allergic rhinitis.
- a method of applying an oral microbiota promoting composition may include multiple instances of introduction of the composition into the oral cavity (mouth) in the form or a solid, powder, paste, or liquid in the amount of about 1 gm to about 500 gms at one time or multiple times in fractional amounts.
- the method may include dissolving the composition in a liquid
- a method of applying an oral microbiota promoting composition may include swallowing the composition following introduction of the composition into the oral cavity and following a period of retaining the composition within the mouth for a select period of time including e.g., chewing, gargling, and/or sublimating (dissolving) the composition while within the oral cavity.
- a method of applying an oral microbiota promoting composition may include removing the composition following introduction into the oral cavity by expelling (e.g., pulling out or spitting-out) the microbiota promoting composition following a period of retaining the composition within the mouth.
- a method of applying an oral microbiota promoting composition may include retaining the microbiota promoting composition within the oral cavity from about 10 seconds to about an hour, more preferably, from about 5 minutes to about 30 minutes on a daily basis for a period of about 2 days to about 60 days.
- a method of applying an oral microbiota promoting composition may include introducing the microbiota promoting composition for relatively short periods several times a day, for example from about 1 second to about 30 seconds, each from about 3 to about 10 times a day for a period of about 2 days to about 60 days.
- a method of applying an oral microbiota promoting composition may include extending the periods of introduction of the microbiota promoting composition into the oral cavity, for example, from about every 3 days to about every 10 days, including stopping the introduction of the composition following the disappearance of allergy symptoms.
- a method of applying an oral microbiota promoting composition may include at least partially removing a mucosal film (biofilm) from within the oral cavity prior to or while administering the microbiota promoting composition to the oral cavity.
- biofilm may be at least partially removed by raising the whole body temperature for a short time, for example, with conventional biological or physical means.
- the biofilm may be at least partially removed by rinsing out (optionally including scrubbing or rubbing) the oral cavity (mouth) with a heated water containing liquid, such as water, at a temperature of from about 90 to about 130 degrees Fahrenheit prior to applying the oral microbiota promoting composition to the oral cavity.
- a heated water containing liquid such as water
- rinsing with a hot water containing fluid may advantageously at least partially remove a biofilm from surfaces within the oral cavity, thereby improving the operation of the oral microbiota promoting composition.
- the oral rinsing may include periodic rinsing, for example, each for about 10 seconds to about 30 seconds over a period of from about 5 to about 15 minutes.
- a method of applying an oral microbiota promoting composition may include at least one of brushing and rubbing portions of the oral cavity with the hot water containing fluid at a temperature of from about 100 to about 130 degrees Fahrenheit including at least the tongue, for example, with at least one of a brush, such as a toothbrush, and/or a wet cloth.
- the oral microbiota promoting composition may be formulated into oral dosage forms such as tablets, caplets, and capsules, or a powder formulation or that may be dissolved in a liquid, for example diluted in a liquid having a ratio of from about 1:1 to about 1:500 with respect to either weight or volume of the liquid (e.g., the liquid being larger number) .
- the oral microbiota promoting composition may be formulated or manufactured as a chewing gum or candy, or other edible carrier, for example as an additive having a ratio of from about 1:1 to about 1:500 with respect to either weight or volume of the edible carrier (e.g., larger number) .
- the oral microbiota promoting composition may be formulated as an additive to an oral hygiene product acting as a carrier, such as toothpaste or mouthwash, the microbiota promoting composition having a ratio of from about 1:1 to about 1:500 with respect to either weight or volume of the oral hygiene product.
- an oral microbiota promoting composition in a method of manufacturing an oral microbiota promoting composition may bo formulated having an edible foodstuff as a carrier, the microbiota promoting composition having a ratio of from about 1:1 to about 1:500 with respect to either weight or volume of the edible foodstuff.
- the desired microbial species/strains promoted in the oral cavity by the oral microbiota promoting composition may be naturally occurring within the oral cavity and/or may be provided separately or within the oral microbiota promoting composition.
- the desired microbial species/strains are present in the oral cavity or in the oral microbiota promoting composition at a level of from about 1000 to about 1,000,000,000 living cells.
- the desired microbial species/strains are naturally occurring and/or may be obtained commercially and handled in accordance with any applicable safety requirements.
- the desired microbial species/strains promoted in the oral cavity by the oral microbiota promoting composition may include at least a first microbial species that can attach to surfaces (e.g., teeth, tongue, mouth) within the oral cavity and at least one second microbial species that may attach to the same or different surfaces and/or may attach to the at least first microbial species .
- the at least a first and second microbial species may produce a product, such as a sugar containing moiety, that may be metabolized by the other of the at least a first and second microbial species.
- one of the desired microbial members promoted within the oral cavity promoted by the oral microbiota promoting composition may include one or more live bacterium with lactate fermenting capability such as, but not limited to Veillonella, which further may include one or more of associated species, such as, but not limited to, V. Dispar and v. Parvula .
- one of the desired microbial species/strains promoted within the oral cavity promoted by the oral microbiota promoting composition may include one or more live lactic acid producing bacterium such as but not limited to Streptococcus including one or more of associated species, such as, but not limited to, S. salivaraus and S. thermophilus .
- the desired microbial species/strains promoted within the oral cavity by the oral microbiota promoting composition may include at least one live lactic acid producing bacterium and at least one live lactate fermenting bacterium such as, but not limited to, respectively, Veillonella and Streptococcus and their respectively associated preferred species stated above.
- an oral microbiota promoting composition is provided that includes at least one amino acid or amino acid containing substance including at least L- arginine.
- the at least one amino acid may further or alternately include at least one of L-cysteine, DL-aspartic acid, L-glutamic acid, L-serine and L-tyrosine including phosphates, salts, acids, and enzymes comprising the same.
- the at least one amino acid may be present in the oral microbiota promoting composition at a weight percent level of from about 0.1 wt. % to about 99.9 wt. %, more preferably, from about 5 wt % to about 95 wt %, even more preferably from about 20 wt % to 80 wt %.
- an oral microbiota promoting composition includes at least one sugar containing substance and at least one amino acid containing substance.
- the at least one sugar containing substance may include at least one monosaccharide, disaccharide, oligosaccharide, and polysaccharide.
- Exemplary monosaccharides may include but are not limited to aldohexoses such as but not limited to mannose including associated isomers, phosphates, salts, acids, and enzymes comprising the same.
- Exemplary disaccharides may include but are not limited to disaccharides including at least one of galactose and glucose, such as but not limited to lactose, sucrose, malibiose, maltose, cellobiose and trehalose (also known as mycose or tremalose) including associated isomers, phosphates, salts, acids, and enzymes comprising the same.
- Exemplary oligosaccharides may include but are not limited to trisaccharides including at least one or more of galactose, glucose, and fructose, such as but not limited to raffinose (also known as melitose) , stachyose, and verbascose, including associated isomers, phosphates, salts, acids, and enzymes comprising the same.
- raffinose also known as melitose
- stachyose also known as melitose
- verbascose including associated isomers, phosphates, salts, acids, and enzymes comprising the same.
- Exemplary polysaccharides may include but are not limited to one or more polysaccharide polymers, such as, but not limited to polysaccharides including malotriose units, including but not limited to pullulan, and fructose polymers, such as, but not limited to inulin and further including associated isomers, phosphates, salts, acids, and enzymes comprising the same.
- polysaccharide polymers such as, but not limited to polysaccharides including malotriose units, including but not limited to pullulan, and fructose polymers, such as, but not limited to inulin and further including associated isomers, phosphates, salts, acids, and enzymes comprising the same.
- the at least one disaccharide may be present in the oral microbiota promoting composition at a weight percent level of from about 0.1 wt. % to about 99.9 wt. %, more preferably, from about 5 wt % to about 95 wt %, even more preferably from about 20 wt % to 80 wt %.
- the at least one oligosaccharide may be present in the oral microbiota promoting composition at a weight percent level of from about 0.1 wt. % to about 99.9 wt. %, more preferably, from about 5 wt % to about 95 wt % , even more preferably from about 20 wt % to 80 wt % .
- the at least one polysaccharide may be present in the oral microbiota promoting composition at a weight percent level of from about 0.1 wt. % to about 99.9 wt. %, more preferably, from about 5 wt % to about 95 wt % , even more preferably from about 20 wt % to 80 wt % .
- the oral microbiota promoting composition may include at least one prebiotic fiber. Exemplary prebiotic fibers may include but are not limited to inulin.
- the at least one prebiotic fiber may be present in the oral microbiota promoting composition at a weight percent level of from about 0.1 wt. % to about 99.9 wt. %, more preferably, from about 5 wt % to about 95 wt % , even more preferably from about 10 wt % to 30 wt % .
- the oral microbiota promoting composition may include additives such as one or more of carbohydrates, amino acids, salts, flavorants, proteins, surfactants, emulsifiers, flavonoids, alcohols, synthetic sweeteners, food preserving agents, and combinations thereof.
- the oral microbiota promoting composition may further include conventional foodstuffs such as one or more of brown sugar, syrup, honey, chocolate, nuts, almonds, spices, cinnamon, and vanilla.
- Example 1 an example of making an edible Foodstuff oral microbiota promoting composition is provided below in Example 1 :
- the above ingredients may be admixed and heated to a temperature sufficient to melt or liquefy, preferably avoiding boiling for an extended period and then poured into a container to cool.
- live bacterium in accordance with safety requirements or limitations, may be added following cooling (e.g., as a coating). It will be appreciated that adding the bacterium may be limited by applicable safety
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201880022770.2A CN110520119A (en) | 2017-04-24 | 2018-04-13 | Oral micropopulation promotes composition and its application method |
| JP2020507984A JP7290869B2 (en) | 2017-04-24 | 2018-04-13 | Composition for Promoting Growth of Oral Microorganisms and Method of Using the Same |
| AU2018257624A AU2018257624B2 (en) | 2017-04-24 | 2018-04-13 | Oral microbiota promoting composition and method |
| KR1020227007264A KR20220034925A (en) | 2017-04-24 | 2018-04-13 | Oral microbiota promoting composition and method |
| KR1020197033975A KR20190141707A (en) | 2017-04-24 | 2018-04-13 | Taken microbial group promoting composition and use thereof |
| EP18790555.9A EP3609488A4 (en) | 2017-04-24 | 2018-04-13 | ORAL COMPOSITION AND METHOD FOR PROMOTING COLONAL |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/495,188 US9795579B1 (en) | 2017-04-24 | 2017-04-24 | Oral microbiota promoting method |
| US15/495,188 | 2017-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018200223A1 true WO2018200223A1 (en) | 2018-11-01 |
Family
ID=60082814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2018/027604 Ceased WO2018200223A1 (en) | 2017-04-24 | 2018-04-13 | Oral microbiota promoting composition and method |
| PCT/US2018/050898 Ceased WO2019055665A1 (en) | 2017-04-24 | 2018-09-13 | An oral microbiota promoting composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2018/050898 Ceased WO2019055665A1 (en) | 2017-04-24 | 2018-09-13 | An oral microbiota promoting composition |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9795579B1 (en) |
| EP (1) | EP3609488A4 (en) |
| JP (2) | JP7290869B2 (en) |
| KR (2) | KR20220034925A (en) |
| CN (1) | CN110520119A (en) |
| AU (1) | AU2018257624B2 (en) |
| WO (2) | WO2018200223A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9795579B1 (en) * | 2017-04-24 | 2017-10-24 | Knoze Jr. Corporation | Oral microbiota promoting method |
| US10842811B2 (en) | 2018-02-28 | 2020-11-24 | The Trustees Of Columbia University In The City Of New York | Inulin for preventing antibiotic resistant infection and pathogen colonization |
| AU2020408410B2 (en) | 2019-12-16 | 2024-03-14 | Colgate-Palmolive Company | Oral care compositions containing inulin |
| US20230045151A1 (en) * | 2020-01-13 | 2023-02-09 | Monash University | Compositions and methods |
| JP2022103980A (en) * | 2020-12-28 | 2022-07-08 | サンスター スイス エスエー | Composition for oral cavity |
| WO2022145325A1 (en) * | 2020-12-28 | 2022-07-07 | サンスター スイス エスエー | Composition for oral cavity |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0441119A2 (en) | 1990-01-09 | 1991-08-14 | Richard D. Levere | The use of L-Arginine in the treatment of hypertension and other vascular disorders |
| US20040258630A1 (en) * | 2003-06-23 | 2004-12-23 | Boyd Thomas J. | Antiplaque breath freshening consumable film |
| US20150182566A1 (en) * | 2007-11-19 | 2015-07-02 | Kaneka Corporation | Lactic acid bacterium-containing preparation |
| US20160304886A1 (en) * | 2013-09-24 | 2016-10-20 | The Regents Of The University Of Michigan | Compositions and method for destabilizing, altering, and dispersing biofilms |
| US20160324766A1 (en) * | 2013-12-27 | 2016-11-10 | Colgate-Palmolive Company | Prebiotic Oral Care Compositions Containing Amino Acids |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790678B1 (en) * | 1999-08-17 | 2010-09-07 | Immunopath Profile, Inc. | Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use |
| CN1396908A (en) * | 2000-01-28 | 2003-02-12 | 宝洁公司 | Delicious Arginine Compounds and Their Applications for Cardiovascular Health |
| WO2006049286A1 (en) * | 2004-11-02 | 2006-05-11 | Ajinomoto Co., Inc. | Preventive/remedy for allergic diseases |
| RU2426438C2 (en) * | 2006-12-06 | 2011-08-20 | ЗАО "Академия-Т" | Synbiotic composition for correction of intestinal tract microbiocenosis abnormalities and enhancement of organism general resistivity and its production methods (versions) |
| ES2665002T3 (en) * | 2007-03-05 | 2018-04-24 | Om Pharma | Bacterial extract for respiratory disorders and procedure for its preparation |
| RU2375923C2 (en) * | 2008-01-18 | 2009-12-20 | ЗАО "Академия-Т" | Special protein product for sport feeding |
| US20100055082A1 (en) * | 2008-09-04 | 2010-03-04 | Jacques Alain Bauer | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
| EP2691089A1 (en) * | 2011-03-31 | 2014-02-05 | Nestec S.A. | Nutritional compositions for increasing arginine levels and methods of using same |
| EP2696868A1 (en) * | 2011-04-12 | 2014-02-19 | Nestec S.A. | Nutritional compositions including branched chain fatty acids and methods of using same |
| WO2014151329A1 (en) * | 2013-03-15 | 2014-09-25 | Aerodesigns, Inc. | Particles for aerosolizing apparatus |
| WO2014200334A1 (en) * | 2013-06-14 | 2014-12-18 | N.V. Nutricia | Synbiotic composition for treatment of infections in allergic patients |
| CN103520719B (en) * | 2013-10-24 | 2016-11-23 | 邹潮 | A kind of buccal antibody product and preparation method thereof |
| CN104435000A (en) * | 2014-11-12 | 2015-03-25 | 江南大学 | Application of lactic acid bacteria for treating bronchial asthma |
| KR101734653B1 (en) * | 2015-06-23 | 2017-05-11 | 서울대학교산학협력단 | Pharmaceutical composition comprising aminoglycoside and probiotics for preventing or treating aphthous stomatitis |
| EP3397076A1 (en) * | 2015-12-29 | 2018-11-07 | N.V. Nutricia | Fermented formula with non-digestible oligosaccharides |
| CN105901678A (en) * | 2016-04-15 | 2016-08-31 | 邵素英 | Agaric probiotic functional food |
| CN106857856A (en) * | 2017-01-14 | 2017-06-20 | 威海紫光科技园有限公司 | It is a kind of to be beneficial to the compound probiotic product of respiratory system |
| US10398670B2 (en) * | 2017-04-24 | 2019-09-03 | Knoze Jr. Corporation | Oral microbiota promotion for oral and/or sinus infections |
| US9795579B1 (en) * | 2017-04-24 | 2017-10-24 | Knoze Jr. Corporation | Oral microbiota promoting method |
-
2017
- 2017-04-24 US US15/495,188 patent/US9795579B1/en active Active
- 2017-09-15 US US15/706,177 patent/US11364217B2/en active Active
-
2018
- 2018-04-13 CN CN201880022770.2A patent/CN110520119A/en active Pending
- 2018-04-13 AU AU2018257624A patent/AU2018257624B2/en active Active
- 2018-04-13 KR KR1020227007264A patent/KR20220034925A/en not_active Ceased
- 2018-04-13 KR KR1020197033975A patent/KR20190141707A/en not_active Ceased
- 2018-04-13 EP EP18790555.9A patent/EP3609488A4/en active Pending
- 2018-04-13 WO PCT/US2018/027604 patent/WO2018200223A1/en not_active Ceased
- 2018-04-13 JP JP2020507984A patent/JP7290869B2/en active Active
- 2018-09-13 WO PCT/US2018/050898 patent/WO2019055665A1/en not_active Ceased
-
2021
- 2021-07-09 JP JP2021114152A patent/JP2021167338A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0441119A2 (en) | 1990-01-09 | 1991-08-14 | Richard D. Levere | The use of L-Arginine in the treatment of hypertension and other vascular disorders |
| US20040258630A1 (en) * | 2003-06-23 | 2004-12-23 | Boyd Thomas J. | Antiplaque breath freshening consumable film |
| US20150182566A1 (en) * | 2007-11-19 | 2015-07-02 | Kaneka Corporation | Lactic acid bacterium-containing preparation |
| US20160304886A1 (en) * | 2013-09-24 | 2016-10-20 | The Regents Of The University Of Michigan | Compositions and method for destabilizing, altering, and dispersing biofilms |
| US20160324766A1 (en) * | 2013-12-27 | 2016-11-10 | Colgate-Palmolive Company | Prebiotic Oral Care Compositions Containing Amino Acids |
Non-Patent Citations (8)
| Title |
|---|
| ARBES,JR. ET AL.: "Oral pathogens and allergic disease: Results from the Third National Health and Nutrition Examination Survey", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 118, no. 5, November 2006 (2006-11-01), pages 1169 - 1175, XP005844194 * |
| CARD ET AL.: "Modulation of Allergic Airway Inflammation by the Oral Pathogen Porphyromonas gingivalis", INFECTION AND IMMUNITY, vol. 78, no. 6, June 2010 (2010-06-01), pages 2488 - 2496, XP055529094 * |
| HAN, CS.: "A specific hygiene hypothesis", MED. HYPOTHESES, vol. 93, August 2016 (2016-08-01), pages 146 - 149 |
| J. CLIN. BIOCHEM. NUTR, vol. 56, 2015, pages 201 - 207 |
| MABALIRAJAN U ET AL., INT. IMMUNOPHARMACOL, vol. 10, 2010, pages 1514 - 1519 |
| OKADA, H.KUHN, C.FOILLET, HBACH, J.F.: "The hygiene hypothesis for autoimmune and allergic diseases: an update", CLIN. EXP. IMMUNOL, vol. 160, 2010, pages 1 - 9 |
| See also references of EP3609488A4 |
| STRACHAN, D.P: "Hay fever, hygiene, and household size", BRITISH MEDICAL JOURNAL, vol. 299, 1989, pages 1259 - 1260 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190141707A (en) | 2019-12-24 |
| JP7290869B2 (en) | 2023-06-14 |
| US11364217B2 (en) | 2022-06-21 |
| WO2019055665A1 (en) | 2019-03-21 |
| US20180303781A1 (en) | 2018-10-25 |
| KR20220034925A (en) | 2022-03-18 |
| EP3609488A1 (en) | 2020-02-19 |
| JP2021167338A (en) | 2021-10-21 |
| JP2020517746A (en) | 2020-06-18 |
| CN110520119A (en) | 2019-11-29 |
| US9795579B1 (en) | 2017-10-24 |
| AU2018257624B2 (en) | 2021-07-08 |
| EP3609488A4 (en) | 2020-05-13 |
| AU2018257624A1 (en) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11083760B2 (en) | Oral microbiota composition for oral and/or sinus infections | |
| AU2018257624B2 (en) | Oral microbiota promoting composition and method | |
| US11478423B2 (en) | Self-film-forming composition for oral care | |
| Muñoz-Sandoval et al. | Effect of bovine milk on Streptococcus mutans biofilm cariogenic properties and enamel and dentin demineralization | |
| CN100586297C (en) | Composition against periodontal bacteria | |
| JP7379152B2 (en) | Composition for inhibiting muscle fibrosis | |
| WO2012039101A1 (en) | Composition for oral use | |
| JP2023168549A (en) | Agent for inhibiting oral cavity pathogenic bacterium from growing, composition for oral cavity, and accelerator | |
| Clark et al. | Effect of commonly prescribed liquid medications on Streptococcus mutans biofilm. An in vitro study | |
| Badiyani et al. | Chocolate disinfectant: effectiveness of cocoa bean husk extract on Streptococcus mutans in used toothbrushes | |
| US10398670B2 (en) | Oral microbiota promotion for oral and/or sinus infections | |
| US11896630B2 (en) | Composition for a formulated oral prebiotic edible composition | |
| JPH10108648A (en) | Residual food additive and oral cavity composition for suppressing dental caries and periodontal disease | |
| US11083759B2 (en) | Oral microbiota transformation for the relief of immune system associated inflammations | |
| US10471033B2 (en) | Oral microbiota promotion for immune system associated inflammations | |
| JP6293177B2 (en) | Oral composition | |
| WO2023110900A1 (en) | Oral care composition comprising enzymes | |
| US20220304967A1 (en) | Oral microbiota promoting composition cross-reference to related applications | |
| Jaffar et al. | Factors responsible for dental caries among patients and its management | |
| Pomakova et al. | Clinical Study of the Change of pH Level in the Supragingival Plaque in Children after Taking Homeopathic Remedies | |
| Bashir | Sweet Bacterial Treats that Prevent Tooth Decay-A Newer Probiotic Approach. | |
| JPH08154585A (en) | Composition for oral cavity for inhibition of sticking and elimination of periodontal pathogenic bacterium | |
| Abd El-Shafy et al. | AL-AZHAR | |
| BR102012032648B1 (en) | composition containing vestitol and neovestitol and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18790555 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2020507984 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 20197033975 Country of ref document: KR Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2018790555 Country of ref document: EP Effective date: 20191115 |
|
| ENP | Entry into the national phase |
Ref document number: 2018257624 Country of ref document: AU Date of ref document: 20180413 Kind code of ref document: A |
